ResMed Inc. (RMD)

240.33 +1.94% (+4.57)

Over 5Y: -11.9%

2026-08-28
150 200 250 300
2021 2022 2023 2024 2025 2026

Financials Quarterly

Q1 '26 — Revenue: 1.3B Q1 '26 — Operating Cash Flow: 457.3M Q1 '26 — Free Cash Flow: 414.4M Q1 '26 — Net Income: 348.5M Q2 '26 — Revenue: 1.4B Q2 '26 — Operating Cash Flow: 339.7M Q2 '26 — Free Cash Flow: 311.2M Q2 '26 — Net Income: 392.6M Q3 '26 — Revenue: 1.4B Q3 '26 — Operating Cash Flow: 554.1M Q3 '26 — Free Cash Flow: 520.5M Q3 '26 — Net Income: 398.7M Q4 '26 — Revenue: 1.5B Q4 '26 — Operating Cash Flow: 454.6M Q4 '26 — Free Cash Flow: 403.5M Q4 '26 — Net Income: 383.4M 0 300M 600M 900M 1.2B 1.5B
Q1 '26 Q2 '26 Q3 '26 Q4 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

7.1
OE margin 27.3%
Oper. margin 33.4%
ROIC 25.8%
Accruals -3.2%
FCF margin 29.2%
OCF margin 31.9%
ROA 17.0%
ROCE 24.9%
ROE 23.1%
Gross margin 61.1%
OCF / EBIT 0.96×

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

5.0
RPO / sales 0.029×
Segment HHI 0.6 HHI
RPO growth —

4 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

9.7
ND/EBITDA —
Cash / Debt 2.2×
Debt / Eq 0.1×
Debt payback 0.0 yr
Quick ratio 2.4×
F-score 7.0 pts
Payout 23.0%
Cash runway —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

4.9
Sales CAGR 4Y +12.1%
Sales/sh Y/Y +10.8%
Shares change -0.87%
Div. growth +12.5%
EBIT CAGR +17.2%
EPS CAGR 4Y +18.4%
EBIT Y/Y +11.9%
EPS Y/Y +9.7%
Sales Q/Q +8.6%
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.